CervoMed (CRVO) announced the appointment of Matthew Winton, Ph.D., as Chief Commercial and Business Officer. Before joining CervoMed, Dr. Winton served as COO at Inozyme Pharma (INZY).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
- CervoMed announces development program, benefits of neflamapimod
- H.C. Wainwright sets CervoMed price target into FDA clarity
- CervoMed price target raised to $31 from $15 at D. Boral Capital
- CervoMed’s Promising Developments and Financial Stability Drive Buy Rating with $20 Price Target
- CervoMed price target lowered to $16 from $20 at Roth Capital